dabigatran etexilate

Health

adminNovember 17, 2020
5

Boehringer Ingelheim receives positive CHMP opinion for use of Pradaxa® (dabigatran etexilate) for the treatment and prevention of venous thromboembolic events in children from birth to less than 18 years of age

Ingelheim, Germany: No approved therapy for the treatment and prevention of venous thromboembolic events in children until now Current standard…
Read More »